The purpose of the Flow Cytometry Shared Resource (FCSR) is to provide comprehensive cytoflourometric analysis and sorting to the YCC investigators and the broader YSM community. The facility not only provides, maintains, and operates the instruments, but also trains users, develops techniques, provides protocols, and manages access and the financial aspects of the Shared Resource. Until the winter of 2004, YSM had two entities that provided FACS services: the YCC FCSR and the Immunobiology (1MB) FACS facility. The former was supported by the YCC grant and user fees while the latter was subsidized in part by Howard Hughes Medical Institute (HHMI), which owned some of the instruments and paid their service contracts. The YCC Shared Resource had a slow-speed sorter and also had access to a FACSCalibur. In winter of 2002, YSM opened a new research building which was to house all of 1MB as well as many YSM faculty members doing immunologically-related research. Using space donated in part by the Dept. of Medicine and in part by Immunobiology (1MB), the school agreed to customdesign space to house an expanded FACS Core that would now be open to 1MB as well as the Dept. of Medicine. In addition, individual units within Medicine donated three FACS Calibur machines to the newly constituted core. At the same time, the FACS Core Director (now YCC FCSR Director) had obtained a shared instrument grant for a new sorter, and a FACS Aria was installed in the fall of 2002. Finally, the YSM purchased for this facility a used MoFlo sorter. Since the YCC FCSR continued to have limited equipment and space, it was decided to improve the quality and scope of services available to YCC members by merging the two facilities. In concert with this, the YCC agreed to partially subsidize the purchase of an LSRII analyzer and to direct its current user subsidy budget towards an employee of the now-merged facility. The facility thus has three high-speed sorters, 4 FACSCaliburs, a FACScan and LSRII. These instruments are housed in TAG S613 and S617, with a Mac and a PC based workstation for data analysis adjacent. It is used by 117 different Pis and has 486 trained users, who together used 3,952 hrs of sorting and 11,915 hrs of analysis in 2005, of which 61 YCC members represented 80% (77% peer-reviewed) and 87% (83% peerreviewed) respectively of total use. Members of 7 of 8 of YCC Research Programs utilized the FCSR.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-30
Application #
7673435
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
30
Fiscal Year
2008
Total Cost
$143,453
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40
Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025
Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331

Showing the most recent 10 out of 675 publications